Alvotech

Alvotech is a public biopharmaceutical company founded in 2013 with its operational headquarters and manufacturing center in Reykjavik, Iceland. The parent company, Alvotech, is a public limited liability company (société anonyme) incorporated in Luxembourg and is listed on the NASDAQ stock exchange in the U.S. and the Nasdaq First North Growth Market in Iceland under the ticker symbol ALVO. As of early 2026, the company had over 1,200 employees and a market capitalization of approximately $1.1 billion. For the full year 2025, Alvotech reported revenues of $586 million.

Alvotech operates as a pure-play biosimilar company, focusing exclusively on the development and manufacturing of biologic medicines that are highly similar to already-approved original biologics. The company's business model is vertically integrated, encompassing cell line development, R&D, and large-scale manufacturing. Its pipeline targets therapeutic areas including autoimmune disorders, ophthalmology, osteoporosis, and cancer. Key biosimilar candidates in its portfolio are designed to compete with major biologic drugs such as AbbVie's Humira (AVT02), Johnson & Johnson's Stelara (AVT04), and Regeneron's Eylea (AVT06).

As an operating company in the biosimilar sector, Alvotech's patent litigation posture is proactive and offensive. The company challenges patents held by the original manufacturers of biologic drugs to clear a path for market entry. This is reflected in the provided data, which shows Alvotech as a plaintiff and not a defendant. Its single tracked case is an action filed at the Patent Trial and Appeal Board (PTAB), a common venue for challenging the validity of existing patents.

The company's most notable tracked litigation is Alvotech v. Regeneron Pharmaceuticals, Inc. This case aligns directly with Alvotech's business strategy, as Regeneron is the manufacturer of the eye-disorder treatment Eylea. Alvotech is actively developing AVT06, its biosimilar version of Eylea, and the PTAB proceeding represents a direct challenge to the patents protecting Regeneron's market exclusivity.